Irreproducibility rates in preclinical experiments exceed 50%, and cost the life science industry nearly $48 billion annually†
Drug development costs have almost doubled over the last decade, increasing from $1.18 billion in 2010 to $2.17 billion in 2018†
Return on investment has decreased 8.2 percentage points over the last decade, from 10.1% in 2010 to 1.9% in 2018†
This whitepaper examines a major contributor to these issues: Avoidable Experiment Expenditure. Research shows that AEE has a significant impact on life science organizations. But it can be resolved.